VAXINIA is under clinical development by Imugene and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I drugs for Hepatocellular Carcinoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VAXINIA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VAXINIA overview
VAXINIA (CF33+hNIS) is under development for the treatment of solid tumor, colon cancer, colorectal cancer, triple negative breast cancer, pancreatic cancer, non-small cell lung cancer, urothelial cancer, metastatic melanoma, bladder cancer, head and neck cancer, hepatocellular carcinoma, renal cell cancers, ovarian cancer, bile duct cancer, liver cancer and gastrointestinal cancer. It is administered through intratumoral and intravenous routes. The drug candidate is a chimeric vaccinia, derived through a recombination of genetic sequences from multi pox virus strains. It comprises of oncolytic virus CF33 with the human sodium iodide symporter (hNIS).
Imugene overview
Imugene is a clinical-stage biopharmaceutical company that focuses on the development of vaccines in the area of oncology. The company develops immunotherapies that activate the immune system of cancer patients to identify and eradicate tumors. The company develops products for the treatment of various tumors including gastric, breast, lung cancers. Imugene’s lead product candidate, CF33 is a chimeric vaccinia poxvirus for the treatment of mixed advanced solid tumors (MAST) and metastatic triple-negative breast cancer. It develops vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes recognized by an antibody with antitumor activity. Imugene is headquartered in Sydney, New South Wales Australia.
For a complete picture of VAXINIA’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
